Biogen Acquires Rights to Multiple Sclerosis Pill
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 8 (Table of Contents)
Published: 5 Aug-2009
DOI: 10.3833/pdr.v2009.i8.1144 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Acorda Therapeutics sold non-US rights to its multiple sclerosis (MS) drug, Fampridine-SR, to Biogen for US$510 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS